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Natural killer (NK) cells belong to the innate immune system and were initially described
functionallywise by their spontaneous cytotoxic potential against transformed or virus-
infected cells. A delicate balance between activating and inhibiting receptors regulates NK
cell tolerance. A better understanding of tissue resident NK cells, of NK cell maturation
stages and migration patterns has evolved allowing a thoughtful evaluation of their modus
operandi.While evidence has been brought up for their relevance as gate keepers in some
hematopoietic malignancies, the role of NK cells against progression and dissemination
of solid tumors remains questionable. Hence, many studies pointed out the functional
defects of the rare NK cell inﬁltrates found in tumor beds and the lack of efﬁcacy of adop-
tively transferred NK cells in patients. However, several preclinical evidences suggest their
anti-metastatic role in a variety of mouse tumor models. In the present review, we discuss
NK cell functions according to their maturation stage and environmental milieu, the recep-
tor/ligand interactions dictating tumor cell recognition and recapitulate translational studies
aimed at deciphering their prognostic or predictive role against human solid malignancies.
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NK CELL FUNCTIONS ARE DICTATED BY THEIR STAGE OF
MATURATION AND THE MICROENVIRONMENT
Natural killer (NK) cells can have distinct functions depending
on their maturation stage and the microenvironment, rendering
complex the physio-pathological role attributed to NK cells. The
majority of mature NK cells circulate in the peripheral blood, but
are also resident in several lymphoid and non-lymphoid organs,
such as the spleen, tonsils, lymph nodes (LNs), liver, lungs,
intestine, and uterus (Shi et al., 2011).
MOUSE NK CELLS
In mice, the phenotype of NK cells is deﬁned among lymphocytes
as CD3−NK1.1+NKp46+. Mature NK (mNK) cells are identi-
ﬁed by the expression of the integrin CD11b (Kim et al., 2002)
and can be further subdivided into various subsets according to
the differentiation marker CD27 (Hayakawa and Smyth, 2006).
In adoptive transfer experiments, CD11b− immature NK (iNK)
cells pass through the CD27+ stage prior to reaching the termi-
nal CD27−CD11b+ stage (Chiossone et al., 2009). CD27+ NK
cells harbored greater cytotoxic function, proliferation capac-
ity, and interferon-γ (IFN-γ) secretion after stimulation with
Abbreviations: AM, alveolar macrophages; CCL2, CC-chemokine ligand 2; CCL5,
CC-chemokine ligand 5; CCR2, CC-chemokine receptor 2; CCR5, CC-chemokine
receptor 5; CCR8, CC-chemokine receptor 8; CD, cluster of differentiation;
CLA, cutaneous leukocyte antigen; CSF1R, colony stimulating factor 1 recep-
tor; CX3CL1, CX3C-chemokine ligand 1; CX3CR1, CX3C-chemokine receptor
1; CXCL10, CXC-chemokine ligand 10; CXCL11, chemokine (C-X-C motif) lig-
and 11; CXCL12, CXC-chemokine ligand 12; CXCR3, CXC-chemokine receptor
3; CXCR6, CXC-chemokine receptor 6; DC, dendritic cell; DSC, decidual stromal
cells; EVT, extravillous trophoblast; GIST, gastrointestinal stromal tumor; HCV,
hepatitis C virus; HLA, human leukocyte antigen; IBD, intestinal bowel diseases;
interleukin (IL)-12 and/or IL-18 than theCD27− expressing coun-
terparts. CXCR3 is exclusively expressed by the CD11b+CD27+
NK cell subset, endowing cells with an active chemotaxis toward
CXCR3 ligands (CXCL10, IP-10, CXCL11) and a preferred migra-
tion to lymphoid tissues (Hayakawa and Smyth, 2006). Hence,
CD11b+CD27− NK cells are considered terminally differentiated,
long-lived cells, preferentially located in non-lymphoid tissues and
exhibiting a functional restriction by self-major histocompatibility
complexes (MHC; Figure 1).
A recent study described a premature NK cell subset (pre-
mNK; Guimont-Desrochers et al., 2012) preceding the CD27+
mNK cell stage. This NK cell stage may correspond to the
interferon-producing killer dendritic cells (IKDC) described in
2006 (Chan et al., 2006; Taieb et al., 2006). Indeed, Taieb
et al. (2006) and others (Chan et al., 2006) described CD11cint
B220+CD49b+NK1.1+MHC-II+ cells sharing both antigen pre-
sentation and cytotoxic functions culminating in anti-tumor
activity (Taieb et al., 2006). Guimont-Desrochers et al. (2012)
showed thatmNK cells fail to acquire B220, even after in vivo stim-
ulation, suggesting that CD11cint B220+ NK cells may not merely
result from NK cell activation (Vosshenrich et al., 2007). They
IFN-α, interferon-α; IFN-γ, interferon-γ; IFNAR1, interferon (alpha, beta, omega)
receptor 1; IL, interleukin; IM, imatinibmesylate; IP-10, interferon gamma-induced
protein 10; KIR, killer cell Ig-like receptor; KLRG1, killer cell lectin-like receptor
subfamily G member 1; MCSF, macrophage colony-stimulating factor; NCR, nat-
ural cytotoxicity receptors; NK cells, natural killer cells; PD-1, programmed cell
death protein-1; PD-L1, programmed cell death 1 ligand 1; RANK, receptor acti-
vator of nuclear factor κB; RANKL, receptor activator of nuclear factor κ-B ligand;
SA, spiral arteries; TRAIL, TNF-related apoptosis-inducing ligand; Treg , regulatory
T cell.
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FIGURE 1 | Maturation stage of NK cells. (A) In mice, the maturation
stage of CD3− NK1.1+ NKp46+ NK cells is deﬁned using both CD27
and CD11b molecule expressions. Upper panel shows relative proportions
of NK cells at steady state in bone marrow (BM), lymph nodes (LN), spleen,
liver, blood, and lungs. Lower panel shows the differentiation of NK cells
based on the expression of CD27 and CD11b. IKDCs expressing B220
and CD11c molecules would be part of a premature NK cell fraction
(pre-mNK) and of a CD27-positive fraction of mature NK cells also
expressing the mannose receptor (CD206). NKreg cells have an immature
phenotype in that they are CD27-positive and CD11b-negative. (B)
In humans, CD19−CD3−CD56+ NK cells are generally deﬁned by
high expression (bright) or intermediate (dim) expression of the CD56
molecule. As in mice, these two populations (CD56bright and CD56dim) are
enriched in separate compartments: CD56bright NK cells predominate in
lymph nodes while CD56dim NK cells predominate in peripheral blood.
Various studies suggested that NK cells expressing CD56dim would be
more terminally differentiated compared to NK cells expressing
CD56bright.
showed that, by 5 days post-transfer, CD11cint B220+CD49b+ NK
cells down-regulatedCD11c,B220, andCD27, andacquiredCD43,
in agreementwith functionalmaturation. By 25 days post-transfer,
all B220+ NK cells had completely lost B220 expression and
exhibited a CD11cneg/low CD11b+CD27− phenotype compatible
with terminally differentiated NK cells. These pre-mNK cells
were actively cycling, a characteristic associated with precur-
sor cell populations (Guimont-Desrochers et al., 2012). Thus,
CD27+ CD11blow CD49b+ CD11cint B220+ NK cells could be
deﬁned as pre-mNK cells, an immediate precursor to CD27+
CD11b+ NK cells. Moreover, our data pointed out that half
of IKDCs were CD11b+. Such CD11b+CD27+IKDCs expressed
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the mannose receptor (CD206) accounting for ovalbumin (OVA)
protein uptake and OVA-speciﬁc CD8+ T cell priming in vivo.
Thus, we reported that the mature fraction of IKDCs could exert
antigen-presentation capacity (Terme et al., 2009).
Interestingly, among the iNKcells (deﬁned asCD11b−CD27+),
we recently identiﬁed a distinct subset endowed with regulatory
functions (that we named “NKreg”). NK cells deﬁned as CD27+
CD11blow c-Kit+ NKp46+ NK cells expressed molecules associ-
ated with immunosuppressive functions (such as CTLA4, Lag-3,
and PDL-1). These Kit+ NK cells accumulated in primary and sec-
ondary lymphoid organs of tumor bearers in an IL-18-dependent
fashion. Blockade of tumor-derived IL-18 markedly prevented
NKreg accumulation andmelanoma dissemination. Kit+ NK cells
operated their immunosuppressive effect by directly killing imma-
ture dendritic cells (DC) and indirectly reducing the pool of
peripheral mNK cells. Anti-PD1 or anti-PDL-1 neutralizing anti-
bodies counteracted all these immunosuppressive effects. Hence,
the adoptive transfer of NKreg cells promoted tumor outgrowth
and metastases spreading (Terme et al., 2012). Our study is in
accordance with others describing iNK cells with regulatory func-
tions. In amousemodel of leukemia, CD49b+ CD90bright c-Kitdim
NK cells expanded; compromised DCmaturation and could blunt
allogeneic T cell proliferation (Ebata et al., 2006). Hence, these
data indicate that distinct subsets of “imNK” could exert intrinsic
inhibitory functions. In addition, mNK may secrete suppressive
cytokines and exert regulatory functions in pathology such as
infections, autoimmunity, and transplantation. Perona-Wright
et al. (2009) showed that NK cells could secrete IL-10 during the
acute phase of systemic infections. NK cell-derived IL-10 ham-
pered the expression of MHC and co-stimulatory molecules and
suppressed the production of pro-inﬂammatory cytokines by DC
(Perona-Wright et al., 2009). In autoimmune disease, NK3-like
cells secreting transforming growth factor beta (TGF-β) could
protect mice against type I diabetes (Zhou et al., 2007). NK cells
promoted allograft tolerance (Beilke et al., 2005) and reduced graft
versus host disease (GVHD) by limiting allogeneic T cell prolifer-
ation (Noval Rivas et al., 2010), presumably through eradication
of myeloid DC.
Finally, NK cells from extra-medullary tissues harboring tissue-
speciﬁc phenotypes suggest that the maturation can be completed
in organ different from bone marrow including thymus, liver,
uterus, and gut. Thymic NK cells have several peculiarities com-
pared with “conventional” NK cells: (i) they express high levels
of IL-7Rα chain (CD127) and the transcription factor GATA-3,
(ii) they produce cytokines but display low natural cytotoxicity,
(iii) they accumulate in LNs (Vosshenrich et al., 2006). Uterine
NK cells promote vascular remodeling and inﬂuence the recruit-
ment and activation of other leukocytes to regulate the physiology
of pregnancy (Santoni et al., 2007). In the liver, bone marrow-
derived NK cells migrate into the liver where they differentiate
into liver-speciﬁc NK cells (Vanderkerken et al., 1993). Hepatic
NK cells display potent cytotoxic capacity expressing high levels
of TRAIL, granzyme B, and perforin molecules (Ochi et al., 2004;
Takeda et al., 2005). A recent study has shown that CD11c+ NK
cells could play amajor role during adenoviral hepatitis (Burt et al.,
2008), these CD11c+ NK cells gained amodest antigen-presenting
cell capacity thus functionally resembling to NKDCs (Pillarisetty
et al., 2005; Plitas et al., 2007) or IKDCs (Taieb et al., 2006). Finally,
CXCL16 (the ligand for CXCR6) is constitutively secreted by
the liver sinusoidal endothelium leading to the accumulation of
CXCR6+ NK cells that represent a consistent fraction of liver
NK cells. CXCR6+ NK cells are drastically reduced in CXCR6
knockout mice. CXCR6-expressing NK cell has been suggested
to develop an adaptive-like immunity, memory NK cell devel-
opment depend on CXCR6 expression by NK cells a chemokine
receptor required for the maintenance of these memory NK cells
(Paust et al., 2010). In themouse intestine, two subsets of NKp46+
cells are present in the gut (Satoh-Takayama et al., 2008). Con-
ventional NK cells secrete IFN-γ and lack expression of RORγt,
whereas RORγt+ NKp46+ cells secrete IL-22 (also called “NK22”)
following stimulation with IL-23 and do not require IL-15 for
their differentiation (Luci et al., 2009). IL-15-dependent NKp46+
NK cells represent the major source of CCL3 during -induced
ileitis leading to the recruitment of CCR1+ inﬂammatory mono-
cytes (Schulthess et al., 2012). However, IL-18 (and not IL-15)
favored CCL3 secretion by these intestinal and pathogenic NK
cells (Schulthess et al., 2012). The authors discussed the possi-
bility that such pathogenic NK cells could cause the recruitment
of inﬂammatory monocytes in Crohn’s disease (Schulthess et al.,
2012). However, it is of note that the precise lineage of gut mucosa
associated-NKp46+ cells remains debated and it is still unclear
if they are developmentally related to the NK cells and/or to the
lymphoid tissue inducer cells or if they represent a distinct innate
immunity cell types (Colonna, 2009; Spits and Di Santo, 2011).
HUMAN NK CELLS
In humans, the blood NK cell pool (CD19−CD3−CD56+ among
lymphocytes) is commonly divided into two distinct subsets,
based on the surface intensity of CD56 expression and the low-
afﬁnity Fc receptor CD16. A major population of CD56dim
NK cells (roughly 90%) expresses high levels of CD16, whereas
a minor subset of CD56bright NK cells fails to express CD16
(Lanier et al., 1986). Moreover, CD56dim NK cells exert high lev-
els of killer cell immunoglobulin-like receptors (KIR) and low
levels of CD94/NKG2 receptors in contrast to CD56bright NK
cells (Figure 1). These two populations were shown to differ
functionally in that CD16low CD56bright are considered more
potent cytokine producers while CD16high CD56dim NK cells
display higher cytotoxic functions. Only CD56dim cells mediate
CD16-dependent antibody-dependent cell-mediated cytotoxicity
(ADCC; Cooper et al., 2001). However, although CD56bright NK
cells can produce high amounts of cytokine after 24 h stimulation
with IL-12 or IL-18, CD56dim cells also produce high quantities
of cytokine after engagement of the activating receptors or after
short-term cytokine stimulation (Fauriat et al., 2010; De Maria
et al., 2011). This notion suggests that extrinsic factors (dictated
bymicroenvironmental cues or soluble factors) may shape NK cell
functions regardless of their “so called maturation stage.” Hence,
CD56dim and CD56bright NK cells differ in their in vivo local-
ization. CD56bright NK cells express chemokine receptors (such
as CCR7, CXCR3, and CD62L) favoring a preferential migration
into lymphoid organs (LN) and a privileged interaction with LN-
residing antigen-presenting cells (Campbell et al., 2001; Cooper
et al., 2001). In contrast, CD56dim NK cells are enriched in tonsils,
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lungs, mucosal sites, and the uterus (Ferlazzo et al., 2004). As a
corollary to themurine data, CD27has been shown to be expressed
by the CD56bright fraction of human NK cells and by LN resident
NK cells in humans (Silva et al., 2008; Vossen et al., 2008). Analo-
gous to the relationship between CD27+ and CD27− mNK cells in
mice, CD27+CD56bright NK cells are considered as the immature
subset of human circulating NK cells (Silva et al., 2008; Vossen
et al., 2008).
Apart from blood and lymphoid tissues, organ-speciﬁc distri-
bution and function of NK cells has been described. NK cells are
present in normal liver and aid to control tolerance and home-
ostasis (Doherty and O’Farrelly, 2000), a dialog between Kupffer
cells and NK cells allowing the tuning of hepatic NK cells dur-
ing infection or liver injury (Tu et al., 2008). Half of hepatic
NK cells are CD56bright CD16low, express CCR7 and CXCR3,
the inhibitory molecule NKG2A and high levels of TRAIL. Liver
TRAIL-expressing NK cells contribute to hepatocellular damage
and clearance of hepatitis C virus (Dunn et al., 2007; Stegmann
et al., 2010). In the uterus (Whitelaw and Croy, 1996), in situ
development of NK cells from precursors is induced by IL-15 and
stem cell factor (SCF). NK cells can also be recruited by extravil-
lous trophoblast (EVT) via CXCL12 secretion. Activated NK cells
secrete IFN-γ that participate in the remodeling of spiral arteries.
Decidual stromal cells secrete TGF-β that results in the down-
regulation of CD16 expression, thus decreasing the ADCC of NK
cells. Expression of HLA-C2 haplotype on EVT predisposes for
preeclampsia (Hiby et al., 2004; Parham, 2004). In the mucosa
surrounding the lymphoid follicles of tonsils and Peyer’s patches
of the ileum/appendix, innate cells referred to as NK22 express the
activating receptorNKp44 aswell as the chemokine receptorCCR6
and may promote mucosal homeostasis (Cella et al., 2009). The
expression of CC-chemokine receptor 8 (CCR8) and cutaneous
leukocyte antigen (CLA) is restricted to human skin-resident NK
cells. Skin NK cells aremostly CD56+/CD16low and display strong
cytotoxic activity against melanoma cells (Ebert et al., 2006).
Collectively, these data support the theory that the maturation
stage of NK cells and environmental factors may cooperate to
shape their functional activities, as already described for other
innate cells such asDC.Although, in steady-state conditions,mNK
cells can be found in some lymphoid and non-lymphoid organs,
following an insult such as a infection, inﬂammation, or cancer,
specialized NK cell subsets can be rapidly recruited to injured
organs to perform their speciﬁc function (elimination of danger)
and/or re-establish tissue integrity.
NK CELLS ARE ABLE TO RECOGNIZE TUMOR CELLS
Tumor cells expose several ligands that can be recognized by NK
cells rendering tumor susceptible to NK cell attack. Interestingly,
accumulating evidences showed that NK cell-mediated elimina-
tion of tumor cells will lead to the subsequent development of
tumor-speciﬁc T cell responses against the parental tumor cells
(Diefenbach et al., 2001; Kelly et al., 2002).
MOLECULES IMPLICATED IN THE RECOGNITION OF TUMORS BY
NK CELLS
Formore than 20 years, several lines of evidence demonstrated the
important role of NKcells in the control of solidmalignancies. The
pioneering demonstration was conducted in the beige mouse in
1980 (Talmadge et al., 1980). Beige mice mimics human Chediak–
Higashi syndrome presenting with defective natural cytotoxicity
against tumor cells. Using a NK cell sensitive (but not resis-
tant) tumor cell line, Talmadge et al. reported increased growth
rate, faster induction time and increased metastatic dissemina-
tion of tumors established in beige compared to control mice.
Later, depletion experiments using anti-asialoGM-1or anti-NK1.1
antibodies concluded to the crucial role of mouseNK cells in keep-
ing in check tumor growth and metastatic spread (Gorelik et al.,
1982; Aboud et al., 1993; Smyth et al., 2001). Conversely, adoptive
NK cell transfer could restore resistance to metastatic spreading,
establishing a causal link between NK cells and tumor control in
wild-type mice (Gorelik et al., 1982; Aboud et al., 1993; Smyth
et al., 2000, 2001; Street et al., 2001). Moreover, a prominent role
for Ly49 receptors (Ljunggren and Karre, 1985; Karre et al., 1986;
Glas et al., 1992, 2000; Koh et al., 2001), NK group 2 member D
(NKG2D) activating receptors (Diefenbach et al., 2001), DNAX
accessory molecule-1 (DNAM-1; Lakshmikanth et al., 2009), and
components of the NK cell secretory and cytotoxic machinery
(Street et al., 2001; Takeda et al., 2011), TRAIL (Taieb et al., 2006)
was reported in the control of tumor growth and metastases in
mice.
In addition, translational research in patients argues on the
role of NK cells in immunosurveillance against cancer (Imai et al.,
2000; Guerra et al., 2008; Kreisel et al., 2012). The KIR (Moretta
et al., 1996) and CD94/NKG2A heterodimers (Braud et al., 1998)
participate in the regulation of NK cell activation by tumor
cells. Indeed, tumor cells can down-regulate MHC class I expres-
sion the missing self-engagement of NK cell activation favoring
tumor elimination (Vivier et al., 2012). Next to this mechanism,
stress-induced molecules also activate NK cells. NKG2D plays an
important role in the recognition of stress-induced molecules
such as the polymorphic MHC class I chain-related molecules
(MIC)A and MICB human (Groh et al., 1996; Bauer et al., 1999)
and the cytomegalovirus UL-16 protein (ULBP; Cosman et al.,
2001). Such proteins are frequently expressed in primary carci-
nomas (Pende et al., 2002; Vetter et al., 2002; Friese et al., 2003;
Watson et al., 2006). The identiﬁcation of two NKG2D haplo-
types associated with differential NK cytotoxic potential and risk
of cancer illustrates the importance of NKG2D in the anti-tumor
immunosurveillance (Hayashi et al., 2006). Natural cytotoxicity
receptors (NCR) are also implicated in the destruction of tumor
cells. All three NCRs are implicated in the clearance of a variety
of tumors, including carcinomas, melanomas, and neuroblas-
tomas. Among self-ligands expressed by tumor cells and able to
activate NK cells, heparan sulfate moieties of heparin sulfate pro-
teoglycans have been described as self-modiﬁed ligands for NCRs
(Jayson et al., 1998; Blackhall et al., 2001), these ligands being rarely
expressed on normal cells (Bloushtain et al., 2004; Hershkovitz
et al., 2007, 2008; Cagnano et al., 2008; Hecht et al., 2009; Jarahian
et al., 2011). NKp30, NKp44, and NKp46 recognize highly sul-
fated heparan sulfate/heparin-type structures (Hecht et al., 2009).
B7 homolog 6 (B7-H6), absent from normal cells but expressed
on the K562 cell line and other acute myeloid leukemia and solid
tumors, was identiﬁed as a ligand for NKp30. Moreover, nuclear
factors (up-regulated or disturbed in their distribution) represent
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alternate ligands for NCRs. Hence, HLA-B-associated transcript 3
(BAT3) was identiﬁed as a ligand for NKp30 activating NK cells.
BAT3 can be either re-localized at the cell surface or expressed on
tumor-derived exosomes shed in the extracellular milieu (Pogge
von Strandmann et al., 2007; Simhadri et al., 2008). Finally, prolif-
erating cell nuclear antigen (PCNA) which is highly expressed in
proliferating cells and associatedwithmalignancy (Stoimenov and
Helleday, 2009) was shown to be recruited in the immunological
synapse formed betweenNK and tumor cells, leading to inhibitory
triggering of NKp44 receptors (Rosental et al., 2011).
NK CELLS CONSTRAIN METASTATIC DISSEMINATION
Several cell autonomous features resulting in NK cell recruitment
and/or activation have been described. Hence, the interferon reg-
ulatory factor irf7 is a key molecule limiting bone metastases in
a NK and CD8+ T cell-dependent manner (Bidwell et al., 2012).
Enforcing irf7 expression by tumor cells could restore type I IFN
signaling, leading to inhibition of metastatic dissemination in
the 4T1.2 breast cancer bone metastasis model (Lelekakis et al.,
1999; Eckhardt et al., 2005). Differences in gene expression pro-
ﬁles of tumor cells isolated frommatched pairs of primary tumors
and bone metastases revealed that a high number of IFN-related
geneswere down-regulated in bonemetastases including irf7 (Bid-
well et al., 2012). 4T1.2 clones overexpressing IRF7 were able to
produce signiﬁcant levels of IFN-α compared to the 4T1.2 con-
trol cell line. 4T1.2-irf7+ presented with reduced dissemination
to the bones in an IFNAR1-dependent manner. Depletion of
CD4+, CD8+, and NK cells demonstrated that CD8+ and NK
cells (but not CD4+ T cells) were needed for the irf7-dependent
anti-metastatic effect (Bidwell et al., 2012). Treatment with 105 IU
of recombinant IFN-α could reduce bonemetastases inmice bear-
ing the 4T1.2 tumors, causing the up-regulation of irf7, irf9, and
STAT1 in the wild-type 4T1.2 cell line. Finally, authors showed
that defective irf7 signaling pathway in human breast cancers was
signiﬁcantly associated with bone metastases as the ﬁrst site of
dissemination (Bidwell et al., 2012). Moreover, irf1 expression by
the tumor was mandatory for NK cell-dependent suppression of
metastases (Ksienzyk et al., 2011). Here, irf1 was implicated in
the suppression of lung metastases, but not tumor spreading to
the bone (Bidwell et al., 2012). Both type I and II IFNs were dis-
pensable for the NK cell-mediated resistance to lung metastases.
Irf1 expression by tumor cells was associated with an increased
CXCL11/CXCR3-dependent NK cell inﬁltration of lung nodules.
Moreover, irf1 could induce tumor cell surface expression of MHC
class I molecules, death receptor DR5 and adhesion molecule
CD155 (ligand for DNAM-1). Hence, NK cell-mediated elimi-
nation of lung metastases was mainly dependent on DNAM-1
receptors and only partially on TRAIL molecules (Ksienzyk et al.,
2011). Altogether, these lines of evidence indicate the cell intrinsic
role of interferon-related pathways in the control of metastatic
dissemination by NK cells. Moreover, various subsets of NK
cells appear to control bone (Bidwell et al., 2012) or lung (Ksien-
zyk et al., 2011) dissemination. Indeed, while CD27+ NK cells
prevailed against bone marrow metastases (Bidwell et al., 2012),
terminally differentiated NK cells seem to control lung metastases
(Sceneay et al., 2012). Indeed, over 80%of lungNKcells aremature
CD11b+ cells.
In contrast, other reports point to a role for myeloid cells
in suppressing the function of mNK in metastatic niches. Sce-
neay et al. (2012) reported that hypoxia at the primary tumor site
led to enhanced secretion of soluble factors that favor metastatic
dissemination. Particularly, under hypoxic conditions, soluble
factors secreted by the primary tumor induce the recruitment
of bone marrow-derived cells in the lungs. Hypoxia caused
the accumulation of granulocytic CD11b+/Ly6Cmed/Ly6G+
myeloid cells through a monocyte chemoattractant protein 1
(MCP1)-dependent mechanism as well as that of iNK cells
(CD11b−/CD27−) endowed with poor anti-tumor effector func-
tions. Authors assume that CD11b+/Ly6Cmed/Ly6G+ myeloid
cells could inhibit NK cell differentiation, as myeloid cell accu-
mulation has been inversely correlated with suppression of NK
cell function in murine tumor models (Liu et al., 2007; Mauti
et al., 2011). In methylcholanthrene-induced carcinogenesis as
well as transplantable metastases models, NLRP3 inﬂamma-
some was shown to support metastases formation. Expansion of
CD11b+ Gr1int myeloid cells within the lung tumor microen-
vironment of NLRP3 knockout mice was concomitant with
increased lung inﬁltrating activated NK cells and an improved
anti-metastatic response. These myeloid cells secreted CCL5 and
CXCL9 chemokines favoring the trafﬁcking of NK cells into
metastatic lungs (Chow et al., 2012).
Considering that NK cells can regulate metastatic dissemina-
tion, it remains unclear whether NK cells are able to modify
the metastatic potential of primary tumor cells and premetastatic
niche and/or could represent an efﬁcient innate barrier that could
prevent tumor cell implantation. To our knowledge, scarce data
exist demonstrating that NK cells could modify tumor cells in the
primary tumor in a way that would decrease metastatic potential.
Some data suggested that NK cells could have cytotoxic activity
against cancer stem cells, which represent a more chemo- and
radio-resistant subpopulation within cancer (Tseng et al., 2010;
Jewett and Tseng, 2011; Jewett et al., 2012). Considering accumu-
lating evidence incriminating tumor stemness as a risk factor for
metastatic relapse (van Zijl et al., 2009; Raimondi et al., 2010; Yu
et al., 2012), high NK cell inﬁltration in the primary tumor could
be a good biomarker associated with low risk of metastatic relapse.
Recently, the epithelial-mesenchymal transition (EMT) process
was linked to the gain of stem cell competence (Mani et al., 2008;
Polyak and Weinberg, 2009). Thus, EMT favors the generation of
tumor cells with self-renewing properties and high proliferative
capacity, enhancing their chances to seed at a distant site and to
grow metastases. Factors that can inﬂuence EMT and/or stemness
such as hypoxia and TGF-β (Das et al., 2008; Heddleston et al.,
2009) are also known to inhibit NK cell functions. Thus, it is con-
ceivable that agents reinvigoratingNK cells in the tumor bed could
decrease its metastatic potential and thus reduce time to relapse.
In humans, NK cell inﬁltration (determined with different
NK cell markers, i.e., CD57, CD56, NKp46, CD3, and CD56)
is often studied on a tumor burden after curative resection. Inter-
estingly, NK cell inﬁltrates are often associated with a lower risk
of relapse and/or longer survival (Table 1). However, in most
cases, NK cell numbers are limited compared with other effec-
tors as reported using tissue microarrays of melanomas (Erdag
et al., 2012; Sconocchia et al., 2012), hepatocellular carcinomas
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Table 1 |Tumor infiltrating NK cells in human cancers.
Cancer Stage Sample
size
Method Markers used for
NK cells analysis
in IHC studies
Results Reference
CRC II–III 93 IHC CD56, CD57 Low tumor stage (P = 0.004), marked CD8+ (P = 0.04, see Figure 2)
and CD57+ (P = 0.05, see Figure 3) cell inﬁltration in the advancing
tumor margin were correlated with a longer disease-free survival in
multivariate analysis
Menon et al. (2004)
CRC II–III 88 IHC CD56 NK cells are rare compare to CD8+ cells (7/mm2 versus 76/mm2).
Surprisingly in tumor with low expression of HLA class I higher
CD8+, but not CD4+ cell inﬁltration was observed
Sandel et al. (2005)
CRC IV 68 IHC CD56 Thirty-three patients were treated with adjuvant FOLFIRI regimen or
FOLFOX with Cetuximab and 35 patients received adjuvant FOLFIRI
regimen or FOLFOX regimen alone. In cetuximab treated patients
only CD56 and K-ras mutation status were independent predictors of
the best overall response and progression-free survival. CD56−
tumors [HR 2.6 (95% CI: 1.14–6.00); P = 0.019] and K-ras mutations
[HR 4.74 (95% CI: 1.8–12.3); P = 0.001] were signiﬁcant
independent negative prognostic markers for the PFS
Marechal et al. (2010)
CRC IV 112 IHC NKp46 Primary tumors and liver metastases were analyzed. Low NK cell
number was detected in tumor and liver metastases. No correlation
between NK cell inﬁltration and chemokine proﬁle within the tumor
tissue or relation between HLA class I expression and NK cell
inﬁltrate were found. In this study no prognostic study was realized
Halama et al. (2011)
CRC I–IV 1414 IHC
(TMA)
CD56, CD57,
CD16
This cohort included a mix of MMR deﬁcient and proﬁcient. CD56
cell inﬁltrate was observed in 38% of CRC. No prognostic role of NK
cells inﬁltrate was determined in this cohort
Sconocchia et al.
(2010)
Gastric
CRC
I–IV 34
18
IHC,
FCM
CD3, CD56 Patients with and without liver metastases were studied. The
number of CD3−CD56+ (mostly CD56dim NK cells) and CD3+CD56+
cells were decreased in metastatic livers compared to those
unaffected by metastases. Interestingly lower CD56+ cell inﬁltration
could be observed in patients with multiple liver metastases
Gulubova et al. (2009)
Gastric
Esophageal
I–IV 50
35
IHC,
FCM
CD56 NK cells inversely correlated with H2O2 production in the tumor
microenvironment. The frequency of CD56dim tumor-inﬁltrating NK
cells decreased according to disease progression
Izawa et al. (2011)
GIST IV 8 IHC,
FCM
CD56 NK cells highly inﬁltrate GIST tumors. An inverse correlation was
observed between NK cell inﬁltrate and metastasis occurrence.
Delahaye et al. (2011)
GIST I–IIIB 47 IHC CD56 Untreated c-Kit-positive primary GISTs were analyzed. NK cells
represent a small fraction of tumor-inﬁltrating immune cells
(34 ± 41 cells/mm2) compared to CD3+ cells (201 ± 331 cells/mm2)
or monocyte-derived cells. No prognostic study was achieved
Cameron et al. (2008)
NSCLC II–IIIA 150 IHC CD57 In univariate analysis, CD57+, deﬁned as CD57high, were associated
with longer survival (P < 0.0002). CD57 cell inﬁltration is a
prognostic factor in univariate analysis, but was not an independent
prognostic factor from classical T and N classiﬁcation in multivariate
analysis
Takanami et al. (2001)
(Continued)
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Table 1 | Continued
Cancer Stage Sample
size
Method Markers used for
NK cells analysis
in IHC studies
Results Reference
NSCLC I–III 335 IHC (TMA) CD56 Multivariate analysis showed that stromal CD56+ cells were
an independent prognostic factor for disease-speciﬁc
survival [HR 2.3 (95% CI: 1.1–5.0), P = 0.031]
Al-Shibli et al. (2009)
NSCLC I–III 28 IHC (Frozen
sections),
FCM
NKp30, NKp46 NK cells inﬁltrating NSCLC are mostly CD56bright NK cells
with impaired cytotoxic capacities against tumor cells
Carrega et al. (2008)
NSCLC I–II 86 IHC, FCM NKp46 NK cells are recruited and localized in the stroma of the
tumor rather than in the tumor nest. NK cells exhibited an
altered phenotype with down-regulated NKp30, NKp80,
CD16, NKG2D, and DNAM-1 while NKp44 and CD69 were
over-expressed. Functional studies showed that tumor
inﬁltrating NK cells had impaired cytotoxic functions
compared to blood NK cells. Prognostic study in this cohort
showed that the presence of NK cells is not associated with
clinical outcome at early stages of the disease
Platonova et al. (2011)
Squamous
cell lung
carcinoma
IA–IIIA 50 IHC CD57 Multivariate analysis including surgical-pathologic stage, age
and endoscopy localization, the risk of death in patients with
less than ﬁve CD57+ cell per ﬁeld was 2.50 fold higher
(95% CI: 1.07–5.85) than in those patients with more than
ﬁve CD57+ cell per ﬁeld
Villegas et al. (2002)
Prostate Gleason
2–10
75 IHC CD56 Forty patients were analyzed after radical prostatectomy and
35 after androgen deprivation therapy. In androgen
deprivation treated patients, high number of CD56 cells was
associated with a lower risk of prostate cancer progression
(P = 0.044), while a high density of CD68 was related to an
increased risk of biochemical recurrence (P = 0.011)
Gannon et al. (2009)
BC I–III 204 IHC (TMA) CD57 CX3CL1 expression correlates with CD8+ and CD57+ cell
inﬁltrations. Tumor stage (I/II versus III), HER-2 status and
CX3CL1 expression were independent prognostic factors for
disease-free and overall survival
Park et al. (2012)
BC I–III 140 IHC, FCM CD56, CD3 In tumor tissue NK cells were enriched with CD56b right cells
with poor cytotoxic potential compared to normal mammary
tissue. An inverse correlation between regulatory T cell and
NK cell inﬁltrates was found. No prognostic study was
achieved.
Mamessier et al. (2011b)
RCC I–IV 117 IHC (TMA) CD56, CD16 No CD56 cell inﬁltrates were detected in 92% of renal cell
carcinomas
Sconocchia et al. (2009)
Melanoma IIIA–IV 183 IHC (TMA) CD56 Very low inﬁltration with CD56+ NK cells is described. CD4,
CD8, and CD20 represented 80% of the immune inﬁltrate in
this cohort
Erdag et al. (2012)
Melanoma
HCC
BC
ND 284
336
385
IHC (TMA) CD56 No CD56 cell inﬁltrate was detected in 71.4% of
melanomas, 92% of hepatocellular carcinomas and 97% of
breast carcinomas
Sconocchia et al. (2012)
CRC, colorectal cancer; NSCLC, non-small cell lung cancer; BC, breast carcinoma; GIST, gastro-intestinal stromal tumor; HCC, hepato-cellular carcinoma; RCC, renal
cell carcinoma; ND, not described.
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(Sconocchia et al., 2012), breast cancers (Sconocchia et al., 2012),
renal cell carcinomas (Sconocchia et al., 2009), and colon rectal
cancers (Sconocchia et al., 2010). Very low NK cell inﬁltration
could be monitored in these different solid tumors, except for
colorectal carcinomas where 38% of tumor samples appeared to
be inﬁltrated by NK cells (Sconocchia et al., 2010, 2012). Fur-
thermore, the activation status of NK cells inﬁltrating the tumor
and/or tumor niches might play a crucial role in tumor clearance
and/or prevention of tumor spreading. Many reports in cancer
patients have demonstrated that NK cells have altered cytotoxic
functions usually correlated with down-regulation of NCR while
tumor cells usually express ligands for these NCR (Menard et al.,
2009; Mamessier et al., 2011a,b; Platonova et al., 2011).
Over the past decade, we investigated the role of NK cells in
the control of gastrointestinal sarcomas (GIST). Unexpected long-
term responses to imatinib mesylate (IM) have been reported in
GIST lacking the hallmark molecular criteria of responses to IM
(Borg et al., 2004; Menard et al., 2009), suggesting that IM might
mediate part of its therapeutic effect by an off-target effect. Indeed,
several mouse tumor cell lines that did not respond to IM in
vitro did so in vivo in immunocompetent mice. This therapeutic
off-target effect of IM was mediated by NK cells and/or special-
ized DC subsets (Borg et al., 2004). We found that, by inhibiting
c-Kit in DC, IM could promote a DC/NK cross-talk that ulti-
mately stimulates NK cells to produce IFN-γ both in mice and in
humans (Borg et al., 2004). Importantly, the IM-induced IFN-γ
production by NK cells represented an independent predictor of
long-term survival in advanced GIST treated with IM (Menard
et al., 2009). Since IM failed to trigger NK cell IFN-γ produc-
tion in about half of GIST patients, we launched a comprehensive
analysis of the GIST-associated NK cell phenotype. At diagnosis,
circulating NK cells from GIST patients (compared with healthy
volunteers) exhibited a selective down-regulation of one particu-
lar type of stimulatory NK cell receptor, NKp30, but not that of
another type, NKG2D, and this NKp30 down-regulation was only
partially restored by IM (Menard et al., 2009). We demonstrated
that the alternative splicing of exon 4, which affects the intracellu-
lar domain of NKp30, generates three membrane-bound proteins
with distinct functions. Indeed, the NKp30a isoform could stimu-
late NK cell degranulation and Th1-type cytokine secretion, while
the NKp30b isoform only signals for Th1 cytokine secretion and
the NKp30c isoform transduced a delayed signal leading to IL-10
secretion. In a cohort of 80 patients with metastatic or recurrent
GIST, the predominant expression of NKp30c was associated with
decreased NKp30-dependent TNFα and CD107a release, com-
pared to patients with high expression of NKp30a and/orNKp30b.
The predominant expression of the NKp30c isoform was an inde-
pendent prognostic factor of reduced overall survival (Delahaye
et al., 2011). Freshly dissociated tumor samples revealed that GIST
are highly inﬁltrated with NK cells (roughly 25% of CD45+ leuko-
cytes were CD3−CD56+ NK cells), and the density of NK cell
inﬁltration was inversely correlated with metastases at diagno-
sis (Delahaye et al., 2011). Altogether, these data again support
a more preventive than curative role for NK cells by counteract-
ing metastatic spread. Since NK cells could play a crucial role
in controlling tumor dissemination in GIST patients, we devel-
oped strategies for boosting NK cells along with IM treatment.
Association of IM and IL-2 has been shown to have potent anti-
tumor responses in mice through activation and trafﬁcking of
IKDC to lung metastases (Taieb et al., 2006). From 2009 to 2012,
we launched a phase I clinical trial in patients with refractory
solid tumors to determine the maximum tolerated dose of IL-
2 combined with 400 mg daily IM. Data from this clinical trial
will be reported soon. If the association appears to be non-toxic,
a phase II study in GIST patients combining these two com-
pounds will be considered. Other NK cell stimulatory compounds
to be used in synergy with IM against GIST could be envisaged
(Figure 2).
Thereby, it seems that NK cells could be a potent effector
cells preventing tumor formation (immunosurveillance) and/or
limiting metastatic spread. Previous study by Imai et al. (2000)
had anticipated this type of conclusion in humans. This 11-year
follow-up study showed a reduced cancer risk among people with
strong ormediumnatural cytotoxic functions in peripheral blood,
suggesting a role for natural immunological host defense mecha-
nisms against cancer. However, and as described above, NK cells
have difﬁculty entering the tumor therefore, strategies that could
increase the penetration and/or proliferation and/or local differ-
entiation of NK cells in the tumor remain attractive. Recently, the
B16F10 transplantable mouse melanoma model transfected with
chemerin, a chemoattractant for NK cells, macrophages, and DC
subsets (Wittamer et al., 2003; Zabel et al., 2005; Parolini et al.,
2007), led to a signiﬁcant recruitment of NK cells in the tumor
responsible for tumor regression (Pachynski et al., 2012). The
authors showed that intra-tumor injection of the recombinant
chemerin was sufﬁcient to obtain tumor regression. Finally, in two
independent clinical cohorts of melanoma patients, retention of
FIGURE 2 |Therapeutic strategies that could increase the functions of
NK cells in patients with GIST. NK cells of patients with high expression
of NKp30a and/or NKp30b isoforms could be reinvigorated using
treatments that are know to favor either direct activation (IL-2, IFN-α, IL-15,
sushi-IL-15) or indirect activation (FLT3, cyclophosphamide) of NK cells
along with imatinib mesylate treatment. Since Balachandran et al. (2011)
have shown that CD8+ T cells could favor tumor regression it is conceivable
to use drugs that will favor CD8T cell activation (anti-PD1 or anti-CTLA4). In
patients harboring the wrong NKp30 proﬁle (high expression of NKp30c
isoform) blocking IL-10 or IL-10 receptor (IL-10R) or using agent that could
modify the NKp30 proﬁle toward the NKp30ab proﬁle (methyltransferase
inhibitors?) might restore the NKp30-dependant NK cells function, thus
favoring the control of tumor growth and/or dissemination.
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high RARRES2 (a gene encoding the chemoattractant chemerin)
expression correlated with better clinical outcomes (Pachynski
et al., 2012).
CONCLUDING REMARKS
We are entering a new era of NK cell investigations in human
malignancies that will open up new avenues for NK cell iden-
tiﬁcation and proﬁling. How NK cell trafﬁcking to tumors
and/or differentiate from precursors in tumors remain an active
conundrum. How NK cells prevent metastases is obscure. How
NK cells regulate adaptive immunity is still debated since NK
can shut down or instead trigger DC or CD4+ T cells. How
to strengthen the functions of NK cells and/or neutralize the
immunosuppressive factors should be harnessed (e.g., IL-2, IL-
15, sushi IL-15, IFN-α, and peptide inhibitors of TGF-β1;
Figure 2).
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